Finerenone has been approved by the FDA to reduce the risk of CV mortality,
Finerenone has been approved by the FDA to reduce the risk of CV mortality,
HF hospitalization, and urgent HF visits in adults with HF with LVEF ≥40%. This decision by the FDA was based on the results of the phase 3 FINEARTS-HF trial.
http://tinyurl.com/